Valion Bio, Inc.
VBIO· Nasdaq
VBIOValion Bio, Inc.
Filed May 16, 2022 · 10-Q · 46 days after period end · 0001410578-22-001666
| Metric | Q1 2022 | Q1 2021 |
|---|---|---|
| Revenue | $428.00K | $323.00K |
| Net Income | -$2.24M | -$1.36M |
| EPS Diluted | -$0.23 | -$0.58 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Valion Bio, Inc. · CIK 1787740 · Engraved from SEC EDGAR
ended Mar 31, 2022 · filed May 16, 2022 · 46 d after period end
